Is Lanxborant a recommended treatment for insomnia?

Lanxborant is Not a Recommended Treatment for Insomnia

Lanxborant is not a recognized or approved medication for insomnia treatment and does not appear in any clinical practice guidelines for insomnia management. The medication name "Lanxborant" does not appear in any of the provided clinical guidelines or research evidence.

Recommended Insomnia Treatments According to Guidelines

First-Line Treatment

• Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as the first-line treatment for chronic insomnia disorder in adults by both the American Academy of Sleep Medicine and the American College of Physicians 1

Pharmacological Options for Insomnia

The American Academy of Sleep Medicine clinical practice guideline (2017) recommends several FDA-approved medications for insomnia treatment 2:

1. Orexin Receptor Antagonists:

   • Suvorexant is suggested for sleep maintenance insomnia 2
   • Newer orexin receptor antagonists like lemborexant have shown efficacy in clinical trials 3, 4

2. Benzodiazepine Receptor Agonists:

   • Eszopiclone for sleep onset and maintenance insomnia 2
   • Zaleplon for sleep onset insomnia 2
   • Zolpidem for sleep onset and maintenance insomnia 2

3. Benzodiazepines:

   • Triazolam for sleep onset insomnia 2
   • Temazepam for sleep onset and maintenance insomnia 2

4. Other Approved Medications:

   • Ramelteon (melatonin agonist) for sleep onset insomnia 2
   • Doxepin (low-dose) for sleep maintenance insomnia 2, 1

Not Recommended Treatments

The guidelines specifically recommend against using:

• Trazodone 2
• Tiagabine 2
• Diphenhydramine 2
• Melatonin (for adults) 2
• Tryptophan 2
• Valerian 2

Orexin Receptor Antagonists in Insomnia Treatment

While "Lanxborant" is not a recognized medication, there are legitimate orexin receptor antagonists approved for insomnia treatment:

• Suvorexant was the first dual orexin receptor antagonist (DORA) approved for insomnia 2, 5
• Lemborexant is a newer DORA that has shown efficacy for both sleep onset and maintenance insomnia 3, 4, 6

These medications work by temporarily blocking the orexin pathway, which promotes wakefulness, rather than enhancing GABA activity like traditional sleep medications 5. This mechanism results in:

• Less morning/next-day impairment
• Reduced motor coordination issues
• Less cognitive impairment
• Potentially lower risk of dependence and tolerance 5, 4

Clinical Considerations for Orexin Antagonists

If considering an orexin receptor antagonist for insomnia:

• Lemborexant is typically started at 5 mg and can be increased to 10 mg if needed 7
• It should be taken at least 7 hours before planned awakening 7
• Common side effects include somnolence (~10%), headache (2-5%), and nightmares (2-5%) 7
• Rare but serious adverse effects may include sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms 7
• Long-term efficacy has been demonstrated beyond 6 months 7

Conclusion

Lanxborant is not a recognized medication for insomnia treatment. For evidence-based insomnia management, clinicians should consider CBT-I as first-line treatment, followed by FDA-approved medications such as orexin receptor antagonists (suvorexant, lemborexant), benzodiazepine receptor agonists, low-dose doxepin, or ramelteon based on the specific sleep complaint pattern and patient characteristics.